Used primarily for the acute treatment of migraines in adults, and also approved for preventive treatment, it works by blocking the activity of calcitonin gene-related peptide (CGRP) receptors, which play a key role in migraine pathophysiology. It is administered orally as a tablet, offering a non-invasive option for patients seeking relief from migraine symptoms. Its efficacy in reducing migraine pain and associated symptoms like nausea and sensitivity to light and sound has been demonstrated in clinical trials. Additionally, it is considered a favorable option for those who prefer to avoid traditional migraine medications such as triptans, especially in patients with cardiovascular risk factors.